Pfizer Inc. $PFE Shares Acquired by Alps Advisors Inc.

Alps Advisors Inc. grew its stake in Pfizer Inc. (NYSE:PFE) by 13.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,099,603 shares of the biopharmaceutical company’s stock after acquiring an additional 128,134 shares during the quarter. Alps Advisors Inc.’s holdings in Pfizer were worth $28,018,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Peak Asset Management LLC lifted its stake in Pfizer by 1.4% during the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock worth $697,000 after purchasing an additional 402 shares during the last quarter. Community Bank & Trust Waco Texas lifted its position in Pfizer by 0.6% in the 3rd quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock valued at $1,703,000 after purchasing an additional 412 shares during the last quarter. Able Wealth Management LLC boosted its position in shares of Pfizer by 2.0% during the second quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock worth $512,000 after buying an additional 413 shares during the period. CVA Family Office LLC boosted its position in Pfizer by 3.3% during the 3rd quarter. CVA Family Office LLC now owns 12,915 shares of the biopharmaceutical company’s stock worth $329,000 after acquiring an additional 413 shares during the period. Finally, Boltwood Capital Management lifted its holdings in Pfizer by 0.7% in the third quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company’s stock worth $1,485,000 after purchasing an additional 420 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 earnings beat and GLP‑1 topline: Pfizer reported upside on revenue and EPS and released positive Phase 2b results for its lead GLP‑1 candidate (strong placebo‑adjusted weight loss), which helped lift sentiment around a new growth leg. Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most
• Positive Sentiment: Management outlines obesity strategy: Pfizer execs signaled the company is “back in the obesity race,” emphasizing development plans and commercialization intent after the encouraging GLP‑1 data. Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data
• Positive Sentiment: FDA grants Priority Review for HYMPAVZI sBLA: The agency accepted a supplemental biologics license application to expand HYMPAVZI’s indication to pediatric and inhibitor populations in hemophilia, which could broaden revenue opportunity if approved. FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA
• Positive Sentiment: Mid‑stage obesity candidate complete: Pfizer announced completion of a mid‑stage trial for PF‑07976016, adding to its GLP‑1/obesity development cadence and potential registration pathway. Pfizer Completes Mid-Stage Trial of New Obesity Drug Candidate PF-07976016
• Positive Sentiment: Pipeline & M&A push into oncology and obesity: Analysts and coverage note Pfizer is lining up ~20 pivotal studies after ~ $9B of 2025 M&A, leaning on Seagen assets and AI tools to accelerate R&D — a multi‑year growth story. Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push
• Positive Sentiment: Income investor attention: Pfizer appears on recent high‑yield dividend stock lists, which can support demand from yield‑focused investors. 3 High-Yield Dividend Stocks Perfect For Retirees
• Neutral Sentiment: Cost‑savings / affordability program: Pfizer launched a TrumpRx program offering discounts on ~30 medicines — positive for patient access and PR, but the near‑term financial impact is unclear. Pfizer Launches Cost-Savings Program on TrumpRx
• Neutral Sentiment: Analyst views mixed: Coverage notes cautious upside — bullish pipeline/AI drivers balanced by execution risk, time to commercialization, and competitive pressure in GLP‑1s. Pfizer Stock Forecast: Trending Analysts See Cautious Upside
• Negative Sentiment: Early‑stage trial halted: Pfizer paused an early‑stage study for PF‑07258669 in older adults, introducing a specific clinical risk that could require program adjustments. Pfizer Halts Early-Stage Trial for PF-07258669 in Older Adults

Pfizer Trading Up 2.8%

PFE opened at $27.24 on Friday. The firm’s fifty day moving average is $25.61 and its two-hundred day moving average is $25.10. The firm has a market cap of $154.88 billion, a PE ratio of 20.03 and a beta of 0.47. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The business had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same period last year, the company earned $0.63 earnings per share. Pfizer’s quarterly revenue was down 1.2% on a year-over-year basis. Equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.3%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio is presently 126.47%.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of research reports. TD Cowen reiterated a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Sanford C. Bernstein restated a “market perform” rating and set a $30.00 price target on shares of Pfizer in a report on Friday, October 31st. Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a report on Wednesday. Citigroup started coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price objective for the company. Finally, The Goldman Sachs Group restated a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $28.06.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.